Pay in 4 interest-free payments of $6.11 Learn more
Ships within 48 hours · Estimated delivery Aug 9 - Aug 14
Evaluation: Body fat (DXA scanning) Lean mass Insulin sensitivity Energy expenditure What they found: The combination showed an additive effect on fat reduction vs monotherapy AOD-9604 partially protected lean mass during GLP-1-induced weight reduction Increased energy expenditure in combination (~3 % vs GLP-1 alone) No new safety signals Why it matters: It validates the concept of combination , the idea that AOD-9604 may not work on its own, but can add value in combination with incretin agonists
The officer accused him of taking a customers money and never providing a product
What is unknown The actual molecular receptor that AOD-9604 binds
Rarely, some people may experience mild, short-term effects like: Redness or irritation at the injection site Temporary tiredness Headaches or nausea (rare) Unlike other weight loss drugs or hormonal therapies, AOD 9604 will not affect blood sugar, IGF-1, or organ growth, making it a safer long-term source of support for metabolism
Your medical history: If you have any concerns about injections, you should discuss your options with a healthcare professional
